Portfolio Highlights
-
Selventa Granted Patent for Discovery of Biomarker Profiles
February 29, 2012 -
Finding satisfaction in stratification
December 8, 2011 -
CardioDx Passes Trial, Determining When Chest Pain Is No Big Deal
November 15, 2011 -
N.C. diagnostics firm LipoScience files for $86M IPO
June 24, 2011 -
Selventa Announces a Joint Technology Collaboration with Pfizer Inc., to Include Developing Knowledge-sharing Portal of Bi Read more: Selventa Announces a Joint Technology Collaboration with Pfizer Inc., to Include Developing Knowledge-sharing Portal of
March 28, 2011 -
TYRX, Inc. raises $20 million in private financing
December 8, 2010 -
Genstruct, Inc. changes name to Selventa as company launches re-branding effort
November 30, 2010 -
TYRX AIGISRx® antibacterial envelope shows low infection rate and high implantation success for CIED procedures
October 19, 2010 -
Gene test may improve heart disease detection
October 4, 2010 -
GE Healthcare forms strategic alliance with cardiovascular genomic diagnostic company, CardioDx
May 13, 2010 -
FDA provides clearance of TyRx antibacterial patch for soft tissue repair
April 27, 2010 -
TyRx announces commercial release of the AIGISRx™ Flat
April 13, 2010 -
TyRx enrolls first patient in CITADEL study for AIGISRx™ anti-bacterial envelope with ICD replacements
March 24, 2010 -
CardioDx - Bringing molecular diagnostics into the cardiovascular arena
March 1, 2010 -
Sequenom licenses worldwide rights to develop age-related macular degeneration diagnostic test
February 9, 2010 -
This New Technology Simply Saved My Legs
December 4, 2009 -
CardioDx completes validation study of first-of-its-kind genomic test for coronary artery disease
August 25, 2009 -
Plaque Piercing Device Relieves Patients' Clogged Arteries
July 2, 2009 -
Tyrx presents early clinical results from AIGISRXTM antibacterial envelope retrospective registry
May 14, 2009 -
Cardiac "Jackhammer" Destroys Arterial Plaque
March 30, 2009 -
Ranch Cardiologist Performs New Surgery
March 26, 2009 -
LipoScience: LDL particle measurement by NMR recognized in consensus statement by the ADA and the ACC
March 27, 2008 -
BioSyntech announces positive preliminary interim data for BST-CarGel® clinical trial
March 17, 2008 -
TyRx Pharma raises $25 million
February 28, 2008 -
FlowCardia launches peripheral CROSSER catheters in the US
December 11, 2007 -
Optherion completes $37 million start up financing
October 9, 2007 -
FlowCardia today announced it has raised $30 million in Series C financing
August 30, 2007 -
FlowCardia, Inc. announces 510(k) clearance for its chronic total occlusion recanalization system
January 23, 2007 -
Significant Decision Gives Patients Better Access to LipoScience's Heart Disease Test
December 2, 2005
Aclara Biosciences
Mountain View, CA
IPO (2000)
Biochip company that developed microfluidic lab-on-a-chip technology with applications for genetic analysis, high-throughput drug screening and clinical diagnostics.
ArgoMed
Cary, NC
Company developed a proprietary, water-induced thermotherapy device and technique to address the non-surgical treatment of benign prostatic hyperplasia (BPH). BPH is a condition that afflicts the majority of men over 60, causing adverse changes in urinary voiding patterns. ArgoMed's initial product received FDA market approval in 1999. Assets acquired by Circon in 2002.
BioSyntech
Laval, Quebec
TSX V: BSY
BioSyntech is a medical device company that specializes in the development, manufacturing and commercialization of advanced biotherapeutic thermogels for regenerative medicine (tissue repair) and therapeutic delivery.
CardioDx
Palo Alto, CA
CardioDx is a cardiovascular molecular diagnostics company developing and commercializing tools to assist cardiologists in the diagnosis of cardiovascular disease. Its lead test, Corus® CAD, is a gene expression algorithm-based blood test for the detection of significant atherosclerotic coronary artery disease.
EBM Solutions
Nashville, TN
Acquired by HealthGate Data Corp. in 2003
Evidence-based medical solutions provider that partnered high-quality health and medical information with ongoing monitoring and analysis of healthcare organizations' online initiatives. Its evidence-based clinical guidelines are backed by independent medical review support through affiliations with Duke University Medical Center, Emory University School of Medicine, Oregon Health and Science University, and Vanderbilt University Medical Center.
Emerald BioAgriculture
Lansing, MI
Emerald is a bioagriculture company developing, manufacturing and marketing biological and biochemical agents to improve crop yields and quality, combat disease and fight pests.
FlowCardia
Sunnyvale, CA
FlowCardia is a medical device company commercializing products for the treatment of chronic total occlusions (CTOs) of coronary and peripheral arteries. Utilizing a technology known as high-frequency mechanical recanalization, the company's CROSSER™ System safely and quickly breaks up CTOs allowing subsequent stent placement or balloon angioplasty and avoiding the trauma of cardiac surgery. FlowCardia's products are marketed throughout much of the United States.
Gentis
Wayne, PA
Gentis is a biomaterials and orthopedics company that has developed and is testing a breakthrough, non-fusion technology for treatment of spinal disc disease. Its lead product, DiscCell, is a radio-opaque implant designed to restore normal biomechanical function of a degenerated or surgically treated intervertebral disc by augmenting or replacing the worn-out gel-like tissue at its center (the nucleus pulposus).
LipoScience
Raleigh, NC
LipoScience is a diagnostic company utilizing nuclear magnetic resonance (NMR) spectroscopy to measure the size and quantity of lipoprotein particles in blood. The company's NMR LipoProfile® blood test is intended to provide a better indication of the risk of developing cardiovascular heart disease than the standard cholesterol test measurements of 'good' and 'bad' cholesterol. The company currently markets and sells the NMR LipoProfile test to physicians, other healthcare professionals, diagnostic laboratories and clinical research clients.
NuVasive
San Diego, CA
Nasdaq: NUVA
IPO (2004)
Medical device company that designs, manufactures and markets minimally invasive spine surgery systems. Its FDA-approved system allows the surgeon to perform common open spine operations through small incisions with a proprietary, easy-to-use guidance system.
Optherion
New Haven, CT
Optherion is an early-stage biotechnology company that is developing therapeutics and diagnostic tools for age-related macular degeneration (AMD) and orphan renal diseases strongly influenced by components of the alternative complement system. Optherion's technologies are based on recent genetic discoveries linking certain genes to these disorders.
Selventa
Cambridge, MA
Selventa (formerly known as Genstruct) is focused on the application of computational systems biology to drug discovery and development. The company is developing disease-specific mechanistic models that are used to discover the mechanisms underlying disease, drug action, and drug efficacy. Pappas Ventures originally invested in Incellico, which was acquired by Genstruct in July 2003.
Sensys Medical
Chandler, AZ
Sensys is developing a non-invasive blood glucose monitor that uses near infrared diffuse reflectance spectroscopy. Once cleared by the Food and Drug Administration, the technology will provide a painless method to collect data for proactive use in controlling diabetes.
TyRx
Monmouth Junction, NJ
TyRx is a medical device company developing a range of drug-eluting implantable devices based on proprietary tyrosine polymer technology licensed from Rutgers University. The company's lead product is AIGIS-Rx™, an antibiotic-eluting mesh envelope into which pacemakers and defibrillators can be inserted prior to surgical implantation, thereby reducing the risk of post-procedure infection.